RESEARCH - Anti-CCP2 assay accurately predicts future development of RA as early as 3 months from onset of symptoms

[Guest guest]

ACR/ARHP Annual Scientific Meeting 2006

Washington, DC November 10-15

Abstract

Title: Anti-CCP2 Assay Accurately Predicts Future Development Of

Rheumatoid Arthritis as Early as 3 Months From Onset Of Arthritic Symptoms

Category: 17. RA - clinical aspects

Author(s): Takashi Yamane1, Kazuko Shiozawa2, Akira Hashiramoto1,

Yasushi Tanaka2, Ken Tsumiyama1, Yasushi Miura1, Shunichi Shiozawa1. 1Kobe

University FHS School of Medicine, Kobe, Japan; 2Rheumatic Disease Centre,

Konan Kakogawa Hospital, Kakogawa, Japan

Presentation Number: 359

Poster Board Number: 359

PURPOSE The early and accurate predictor of the future development of

rheumatoid arthritis (RA) was sought for in the patients who first visited

hospital complaining any of arthritic symptoms after several months from

onset.

METHODS 435 patients who first visited hospital within 24 months after

the onset of arthritic symptoms, including 261 first visitors within 6

months, were studied prospectively for 9.2±11.0 months. Anti-CCP antibody

(Ab) was measured by anti-CCP2 ELISA simultaneously with other clinical and

laboratory parameters on their first visit.

RESULTS The frequency of anti-CCP2-positive individual was 50.0% at 1

month from onset and was gradually increased during disease course in the

patients with final diagnosis of RA. For the patients who first visited

hospital within 3 months from onset, the diagnostic specificity and positive

predictive value (PPV) of anti-CCP2 assay, a predictor for future

development of RA, were 95.4% and 87.8%. Those of anti-CCP2 assay plus

rheumatoid factor (RF) were 97.2% and 90.9%. For the patients who first

visited later than 3 months but within 24 months from onset, however,

predictive accuracy of anti-CCP assay declined. Accordingly, we sought for

another criteria and found that the specificity and PPV were 98.7% and

95.5%, respectively, when anti-CCP2 assay was co-evaluated with RF,

C-reactive protein (CRP) and swollen joints. These values surpassed those of

ACR criteria, and thus one can predict future development of RA with high

accuracy. For routine clinical use, co-evaluation of anti-CCP2 assay either

with: (1) RF plus swollen joints; (2) CRP plus swollen joints; or (3) RF

plus CRP would also be highly accurate enough, which gave the specificity

and PPV values exceeding 96% and 92%, respectively.

CONCLUSIONS Anti-CCP2 assay accurately predicts future development of

RA from as early as 3 months until 24 months from onset of arthritic

symptoms when RF, CRP and/or swollen joints are co-evaluated. Routine

clinical use of anti-CCP2 assay is highly recommended.

http://abstractsonline.com/viewer/viewAbstractPrintFriendly.asp?CKey={A1E76754-2\

031-49E8-937C-4F23F3611D3E} & SKey={B3F82403-B1A4-46E5-9557-3DB49A84FCCA} & MKey={C2\

97FAF7-2B4C-45F5-A662-0972E559ED7D} & AKey={AA45DD66-F113-4CDD-8E62-01A05F613C0D}'\

,500,400)

Not an MD

I'll tell you where to go!

Mayo Clinic in Rochester

http://www.mayoclinic.org/rochester

s Hopkins Medicine

http://www.hopkinsmedicine.org